



Prescription Drugs in MN: What We Know and Don't Know

Jan K. Malcolm, Commissioner Stefan Gildemeister, Director Health Economics Program

Overview

- Policy initiatives in other states
- What we know in Minnesota
- What we don't know (and probably should)


2019 State Legislatures Aim to Curb Drug Spending

In 2019, 29 states passed 46 new laws to curb Prescription Drug Spending	
Pharmacy Benefit Manager	22
Wholesale importation	4
Study language	4
Drug price transparency	5
Volume purchasing	2
Drug affordability review (rate setting)	2
Coupons	3
Other	4


Fill gaps in information/address opaqueness:

- Strengthen transparency
- Understand reimbursement practices, price setting, role of rebates, high out-ofpocket costs, access, use of industry revenue, etc.)
- Explore a range of policy options (UPL, common formularies, setting expenditure goals)


Trends in Retail Prescription Drug Spending in MN




Rx Volume and Spending in Pharmacy & Medical Benefits




Spending by Therapeutic Categories, 2013



Drug Spending Growth is Driven By a Range of Factors



Percent of Minnesotans Who in 2017 Did Not Fill a Prescription Due to Cost



These are the rates of Minnesotans who reported they did not fill a prescription, broken down by demographic categories. The lines indicate the rate of Minnesotans who did not fill a prescription statewide (9%) and by whether they had a chronic condition (16%) or not (5%).

The statewide rate equals about 500,000 Minnesotans who have reported not filling a prescription. About 330,000 of these have a chronic condition and about 170,000 did not report a chronic condition.

*Indicates a statistically significant difference from the overall statewide rate (9%) at the 95% level.

Source: MDH/Health Economics Program analysis of the Minnesota Health Access Survey, 2017.

State of Evidence

Ongoing gaps in evidence

- Affordability of Rx use & benefit design for specific therapies
- Patterns of Rx therapy use and access across age & geography
- Role of rebates & discounts
- Economic & clinical value of Rx
- Role of actors in pricing across the supply chain & market forces
- Impact of Rx prices on outcomes & health
- Etcetera.

Other work underway

- Opioid prescribing patterns & new chronic use
- High-cost/ high volume drugs
- Adverse drug events
- Pediatric use (and variation in use) of certain Rx therapies
- Public use files





Thank You!

Health Economics Program: www.health.state.mn.us/healtheconomics

MN All Payer Claims Data: www.health.state.mn.us/data/apcd/publications.html

Health Care Market Statistics: www.health.state.mn.us/data/economics/chartbook/

Contact: <u>Stefan.Gildemeister@state.mn.us/</u> 651.201.3550